AI-driven drug discovery continued to attract large pharma partnerships: Insilico Medicine signed an agreement with Servier reportedly worth up to $888 million focused on oncology R&D, while Earendil Labs secured a separate AI discovery pact with Sanofi that could exceed $2 billion for autoimmune and inflammatory targets. Press releases and IPO coverage framed both deals as validation of AI platforms for target identification and early discovery. Each collaboration includes up-front and near-term payments and milestones tied to candidate discovery and preclinical progress. Companies emphasized complementarities — Insilico’s Pharma.AI and Earendil’s platform with incumbent pharma development capabilities — and signaled the deals will fund platform scale-up and candidate advancement. Observers noted the deals underscore biotech-pharma appetite to buy AI-enabled speed and candidate throughput at an early stage.